ZOLL Medical Corporation has agreed to acquire Cardiac Science Corporation, a provider of automated external defibrillators, related services and accessories. No financial terms were disclosed. CSC is a portfolio company of Aurora Resurgence.
DEERFIELD, Wis.–(BUSINESS WIRE)–Cardiac Science Corporation (CSC), a leading provider of automated external defibrillators (AEDs), related services and accessories, today announced it has entered into a definitive agreement to be acquired by ZOLL® Medical Corporation, an Asahi Kasei Group Company that manufactures medical devices and related software solutions. CSC is a portfolio company of Aurora Resurgence, a Los Angeles-based private equity firm.
Together, the combined company will be equipped to provide a broad range of technologies and services to address current needs, and the resources and vision to lead next-generation innovation. Specifically, the combination of Cardiac Science’s Rescue Ready® Services and ZOLL’s program management portfolio will result in the largest single database of AED information, improving first responder access to AEDs and in turn, their ability to respond to victims of cardiac arrest.
“We are enthusiastic that ZOLL is the right company to champion our high-quality AED portfolio, leveraging its footprint and vision to expand access and applications for use in communities worldwide,” said Dev Kurdikar, President and CEO of Cardiac Science. “The agreement reflects ZOLL’s appreciation for the value of our technology, and I am confident customers will benefit from the increasing resources and reach of our combined portfolios.”
Cardiac Science continues to introduce new solutions this year that improve ease of use and performance of AED systems, strengthening its robust portfolio and record of quality.
“We see considerable complementary features in the two portfolios and look forward to adding the Cardiac Science technology to the services we offer our customers,” said Elijah A. White, President of ZOLL Resuscitation. “In fact, the opportunities we gain by sharing the expertise, technologies and accessories of each legacy organization will dramatically improve the utility of our combined portfolio.”
As part of the agreement, ZOLL will acquire Cardiac Science’s product portfolio and pipeline, along with its facilities in the United States and Europe. Additional terms of the agreement are not being disclosed. The acquisition is subject to anti-trust regulatory approval and other customary closing conditions. Until closing, the companies will operate independently.
About Cardiac Science Corporation
Cardiac Science develops, manufactures, and markets automated external defibrillators (AEDs), as well as AED parts and accessories. The company also offers Rescue Ready® Services, a comprehensive portfolio of training, maintenance, and support services for AED customers. Cardiac Science has executive offices in Deerfield, Wisconsin. The company has operations in North America, Europe and Asia and has an installed base of over 500,000 units in nearly 100 countries worldwide. For information, visit http://www.cardiacscience.com.
About ZOLL Medical Corporation
ZOLL Medical Corporation, an Asahi Kasei Group company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, therapeutic temperature management, and ventilation, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and acute critical care. For more information, visit www.zoll.com.
About Asahi Kasei
The Asahi Kasei Group is a diversified group of companies led by holding company Asahi Kasei Corp., with operations in the material, homes, and health care business sectors. Its health care operations include devices and systems for acute critical care, dialysis, therapeutic apheresis, transfusion, and manufacture of biotherapeutics, as well as pharmaceuticals and diagnostic reagents. With more than 30,000 employees around the world, the Asahi Kasei Group serves customers in more than 100 countries. For more information, visit www.asahi-kasei.co.jp/asahi/en/.